Company intelligence / Profile preview
CHA Vaccine Institute
Seongnam-si, Gyeonggi-do, South Korea
- Ownership
- Private
- Development stage
- Other
01
Overview
Three clinical-stage vaccine/immunotherapy programs active: one lead therapeutic vaccine for chronic hepatitis B entering Phase 2b, two prophylactic vaccines (HBV, herpes zoster) advancing through Phase 1. L-pampo adjuvant platform demonstrates significant immune potentiation in clinical studies; herpes zoster vaccine Phase 1 expected readout in 2025.[1][8][9]
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineRecombinant proteinBiologicAdjuvant
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on CHA Vaccine Institute.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CHA Vaccine Institute.